CD274 and non-small cell lung carcinoma: With a median OS of 62 months for patients with blood group O compared to only 19 months for other ABO‐blood groups (PFS: BG O: 39 months versus other ABO‐BG: 4 months), our study demonstrates that immunotherapy alone could be sufficient for patients with metastatic NSCLC with high PD‐L1 expression and blood group O. Interestingly, an OS and PFS benefit was lacking in the ABO‐blood groups in the chemoimmune cohort (CIC) and the historical chemotherapy control cohort/CCC.